
A New Hope for Epidermolysis Bullosa (“butterfly children”) Thanks to Novel CRISPR-Cas3 Platform
Healiva SA (Healiva) and C4U Corporation (C4U) are pleased to announce that they have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also…










